<DOC>
	<DOCNO>NCT00033540</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine capecitabine , use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine gemcitabine capecitabine treat patient locally advance metastatic gallbladder cancer cholangiocarcinoma .</brief_summary>
	<brief_title>S0202 Gemcitabine Capecitabine Unresectable Locally Advanced Metastatic Gallbladder Cancer Cholangiocarcinoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate ( confirmed complete partial response ) patient unresectable , locally advanced metastatic gallbladder cancer cholangiocarcinoma treat gemcitabine capecitabine . - Determine overall survival patient treat regimen . - Determine quantitative qualitative toxic effect regimen patient . - Determine feasibility accrue patient disease site . - Evaluate , preliminarily , relevant prognostic marker disease sit prognostic implication predictor survival patient treat regimen . OUTLINE : This multicenter study . Patients receive oral capecitabine twice daily day 1-14 gemcitabine IV 100 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month disease progression every 6 month 3 year . PROJECTED ACCRUAL : A total 20-40 patient accrue study within approximately 10-20 month .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm gallbladder cancer cholangiocarcinoma Locally advance metastatic disease unresectable Eligible subtypes : Adenocarcinoma , intestinal type Adenocarcinoma , otherwise specify ( NOS ) Papillary carcinoma Clear cell adenocarcinoma Mucinous carcinoma Signet ring cell carcinoma Squamous cell carcinoma Adenosquamous carcinoma Small cell carcinoma Undifferentiated carcinoma Carcinoma , NOS OR Histologically confirm adenocarcinoma metastatic site clinical documentation* gallbladder bile duct involvement evidence another primary NOTE : *If clinical documentation gallbladder bile duct involvement possible due removal organ , clinically and/or radiographically consistent picture plus pathologic finding metastatic site consistent cholangiocarcinoma allow Measurable disease locate outside prior radiotherapy port No carcinoid tumor sarcomas PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) Serum glutamic pyruvic transaminase ( SGPT ) great 2.5 time ULN ( 5 time ULN liver metastasis present ) Renal : Creatinine clearance least 30 mL/min Cardiovascular : No clinically significant cardiac disease well control medication No congestive heart failure No symptomatic coronary artery disease No cardiac arrhythmias No myocardial infarction within past 12 month Gastrointestinal : Able swallow and/or receive medication via gastrostomy feed tube No intractable nausea vomit No malabsorption syndrome Other : No severe reaction fluoropyrimidine therapy know hypersensitivity fluorouracil No malignancy within past 5 year except : Adequately treat basal cell squamous cell skin cancer Carcinoma situ cervix Adequately treat stage I II cancer currently complete remission Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Prior neoadjuvant adjuvant immunotherapy allow provided therapy complete least 1 year document recurrence metastatic disease No concurrent immunotherapy Chemotherapy : Prior neoadjuvant adjuvant chemotherapy chemoradiotherapy allow provided therapy complete least 1 year document recurrence metastatic disease No concurrent chemotherapy Endocrine therapy : Prior neoadjuvant adjuvant hormonal therapy allow provided therapy complete least 1 year document recurrence metastatic disease No concurrent hormonal therapy Radiotherapy : See Disease Characteristics See Chemotherapy Recovered prior radiotherapy Prior neoadjuvant adjuvant radiotherapy allow provided therapy complete least 1 year document recurrence metastatic disease No prior radiotherapy 25 % bone marrow No concurrent radiotherapy except palliation metastatic site consider target lesion Surgery : At least 2 week since prior surgery malignancy recover Other : No prior treatment metastatic disease No concurrent therapy cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>adenocarcinoma gallbladder</keyword>
	<keyword>adenocarcinoma squamous metaplasia gallbladder</keyword>
	<keyword>squamous cell carcinoma gallbladder</keyword>
	<keyword>adenocarcinoma extrahepatic bile duct</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>cholangiocarcinoma extrahepatic bile duct</keyword>
</DOC>